[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

United Therapeutic (UTHR)

United Therapeutic (UTHR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

United Therapeutic 1000 SPRING ST SILVER SPRING MD 20910 USA

www.unither.com Employees: 1,400 P: 301-608-9292

Sector:

Medical

Description:

United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets.

Key Statistics

Overview:

Market Capitalization, $K 24,857,482
Enterprise Value, $K 23,300,382
Shares Outstanding, K 43,828
Float, K 39,314
% Float 89.70%
Short Interest, K 2,837
Short Float 6.47%
Days to Cover 4.11
Short Volume Ratio 0.56
% of Insider Shareholders 10.30%
% of Institutional Shareholders 94.08%

Financials:

Annual Sales, $ 3,183 M
Annual Net Income, $ 1,335 M
Last Quarter Sales, $ 790,200 K
Last Quarter Net Income, $ 364,300 K
EBIT, $ 1,493 M
EBITDA, $ 1,578 M

Growth:

1-Year Return 91.34%
3-Year Return 146.45%
5-Year Return 181.39%
5-Year Revenue Growth 114.57%
5-Year Earnings Growth 141.42%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 7.70 on 02/25/26
Next Earnings Date 05/06/26 [BMO]
Earnings Per Share ttm 27.90
EPS Growth vs. Prev Qtr 7.54%
EPS Growth vs. Prev Year 24.39%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 09/23/09

UTHR Ratios

Ratio
Price/Earnings ttm 20.53
Price/Earnings forward 20.53
Price/Earnings to Growth 1.63
Return-on-Equity % 19.30%
Return-on-Assets % 17.29%
Profit Margin % 41.94%
Debt/Equity 0.00
Price/Sales 7.89
Price/Cash Flow 17.41
Price/Book 3.48
Book Value/Share 164.80
Interest Coverage 88.89
60-Month Beta 0.75
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.